BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21040579)

  • 21. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].
    Gawkowska-Suwińska M; Turska M; Roskosz J; Puch Z; Jurecka-Tuleja B; Handkiewicz-Junak D; Wygoda Z; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():278-88. PubMed ID: 12182036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine ablation: when and how.
    Ambrosetti MC; Colato C; Dardano A; Monzani F; Ferdeghini M
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):473-81. PubMed ID: 19910900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
    Kusacic Kuna S; Samardzic T; Tesic V; Medvedec M; Kuna K; Bracic I; Despot M; Dodig D
    Nucl Med Commun; 2009 Apr; 30(4):263-9. PubMed ID: 19247212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine ablation of thyroid remnants in patients with differentiated thyroid carcinoma (DTC) following administration of rhTSH - a comparison with L-thyroxine withdrawal.
    Bałdys-Waligórska A; Gołkowski F; Krzentowska-Korek A; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2010; 61(5):474-9. PubMed ID: 21049461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131).
    Prpic M; Dabelic N; Stanicic J; Jukic T; Milosevic M; Kusic Z
    Ann Nucl Med; 2012 Nov; 26(9):744-51. PubMed ID: 22829399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Dynamic Risk Stratification Decreases Rate of Ablative and Adjuvant Radioiodine Use in ATA Low and Intermediate Risk Papillary Thyroid Cancer Patients.
    Gorur SK; Ozbas S; Ilgan S
    Sisli Etfal Hastan Tip Bul; 2023; 57(4):451-457. PubMed ID: 38268648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
    Molinaro E; Pieruzzi L; Viola D
    J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parameters Influencing Curative Effect of 131I Therapy on Pediatric Differentiated Thyroid Carcinoma: A Retrospective Study.
    Xu L; Liu Q; Liu Y; Pang H
    Med Sci Monit; 2016 Aug; 22():3079-85. PubMed ID: 27576533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
    Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
    Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of ultrasound examination in the detection of neck recurrence in low-risk differentiated thyroid carcinoma patients at first follow-up visits.
    Moslehi M; Assadi M
    Nucl Med Rev Cent East Eur; 2014; 17(1):3-6. PubMed ID: 24610645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer.
    Saraçoğlu S; Güven O; Babacan GB; Karyağar S; Özülker T; Ergür S; Sağlampınar Karyağar S
    Mol Imaging Radionucl Ther; 2023 Jun; 32(2):112-116. PubMed ID: 37337764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment.
    Bal C; Ballal S; Soundararajan R; Chopra S; Garg A
    Cancer Med; 2015 Jul; 4(7):1031-8. PubMed ID: 25755077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.